ANHUI JIARUO IMPORT AND EXPORT CO.,LTD

Manufacturer from China
Active Member
4 Years
Home / Products / Rapid Test Kits /

Disaposable Medical One Step Test For SARS-CoV-2 Antigen Colloidal Gold

Contact Now
ANHUI JIARUO IMPORT AND EXPORT CO.,LTD
City:hefei
Country/Region:china
Contact Person:MrWang
Contact Now

Disaposable Medical One Step Test For SARS-CoV-2 Antigen Colloidal Gold

Ask Latest Price
Brand Name :Getein
Model Number :JR-CG
Certification :CE
Place of Origin :China
MOQ :To be negotiated
Price :To be negotiated
Payment Terms :L/C, T/T
Supply Ability :2000000 set per month
Delivery Time :To be negotiated
Packaging Details :To be negotiated
Product Name :One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)
Use :For Professional Use
Specifications :25 Tests/Kit
Size (cm) :20*16*6.5
Weight/Kit (g) :322 g
Kit Quantity/Carton :24 Kits/Carton
Size of Carton (cm) :44*42*35.5
Weight per Carton (kg) :8.91 kg/Carton
Certificates :CE
Sterility :Non-sterile
more
Contact Now

Add to Cart

Find Similar Videos
View Product Description

Professional Use Disaposable Medical One Step Test For SARS-CoV-2 Antigen Colloidal Gold Rapid Test

Product Name One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)
Use For Professional Use
Specifications 25 Tests/Kit
Certificates CE
Kit Quantity/Carton 24 Kits/Carton
Size (cm) 20*16*6.5
Weight/Kit (g) 322

Disaposable Medical One Step Test For SARS-CoV-2 Antigen Colloidal Gold

Stability:
1. Store the test card at 4 - 30°C with a valid period of 24 months.
2. Use the test card within 1 hour once the foil pouch is opened.
3. Store the sample extraction solution at 0-30°C with a valid period of 24 months.
4. Store the sample extraction solution at 2-8°C for better results.

Note:

1. Positive results indicate the presence of SARS-CoV-2 antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. A positive result does not rule out co-infections with other pathogens.

2. Negative test results do not preclude infection and should not be used as the sole basis for treatment or other patient management decisions, including infection control decisions, particularly in the presence of clinical signs and symptoms consistent with COVID-19, or in those who have been in contact with the virus. It is recommended that these results be confirmed by a molecular testing method, if necessary, for patient management.

Inquiry Cart 0